2025 Q3 -tulosraportti
14 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 250
Myynti
Määrä
2 709
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | AVA | ||
| 2 419 | NON | NON | ||
| 509 | NON | NON | ||
| 401 | NON | NON | ||
| 1 090 | NON | NON |
Ylin
9,72VWAP
Alin
9,14VaihtoMäärä
0,7 78 737
VWAP
Ylin
9,72Alin
9,14VaihtoMäärä
0,7 78 737
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 17 416 | 9 163 | +8 253 | 0 |
| Nordea Bank Abp | 5 604 | 490 | +5 114 | 0 |
| Avanza Bank AB | 10 091 | 5 603 | +4 488 | 750 |
| Danske Bank A/S | 2 451 | 0 | +2 451 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 600 | +400 | 0 |
| Svenska Handelsbanken AB | 0 | 840 | −840 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 42 510 | 59 276 | −16 766 | 31 778 |
| Swedbank AB | 0 | 3 100 | −3 100 | 0 |
| Svenska Handelsbanken AB | 0 | 840 | −840 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 600 | +400 | 0 |
| Danske Bank A/S | 2 451 | 0 | +2 451 | 0 |
| Avanza Bank AB | 10 091 | 5 603 | +4 488 | 750 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenHow much further down do we expect it to go in the next couple of weeks/months? And how far along are they with finding a patient for dosing?
1 t sitten1 t sittenTämä kommentti on poistettu.
·1 t sittenAccording to the protocol for this trial, it will conclude in May. But it may well be that they conclude it earlier depending on how quickly they achieve the desired number of patients. I think the next trial will come as soon as possible after if this trial has good results. If adjustments etc. need to be made, then it's impossible to know when the next trial will start. uTREAT is still untested. But both the binding to uPAR and the use of Lutetium-177 are known. Lutetium-177 is already approved for cancer treatment. So I maintain faith even if the first trial doesn't go 100% as hoped.
·4 t sittenIt's surely a strong signal that CURA both announces and executes a directed issue at or around the same time after close, and now holds an extraordinary general meeting, among other things, to allow a third-party lender to come into play: "The Board plans to use the authorization to issue a convertible loan note to a third-party lender who supports the planned Directed Issue, as described in the press release dated December 12, 2025 as part of the agreement with the aforementioned third-party investor." 💪
·3 t sittenA scenario could well be that it reaches 11-12 before the year is over It's probably not crazy to call this a power move. I am truly impressed, because the timing is nothing short of fantastic and the issue has been completely dismantled, allowing full focus on the pipeline I am 90% sure that in a month, not only will it be forgotten, but it will stand as a decisively correct move from management's side. In addition to gaining peace for the pipeline, one also gains peace for potentially being acquired without having to sell oneself too cheaply.
·5 t sittenPositive with more media coverage this morning, I wonder if we'll get a bit more attention around Curasight and their groundbreaking research in the near future - which will certainly also positively affect the stock.! Exciting week ahead….- ·5 t sittenMany of the sellers in this case are "behind the curve" sellers. Hobby investors who are tired of themselves and that they have gambled the family's savings and in the name of greed failed to sell at 11-12 So they are selling now and entering too late again, and selling too late and buying too late etc. People need to take a breath. YES it will fall the next few days, but just check the development since summer and consider that this directed issue was a bullseye in terms of speed and timing. A huge victory for existing investors, who now avoid an ugly moment of uncertainty for the next 7-8 weeks.
·5 t sittenInteresting to see if people sell in panic and forget all about the good that awaits just around the corner
·5 t sitten · MuokattuNo, it's good timing, The cash register would have been empty during February (= ongoing operation of the company would be at risk). The share price is high now while we await FPD and effect at uTREAT. They have received 16.4 mill to secure ongoing operations (share price 8) against limited dilution. They have refinanced loans for 10 mill. and secured new loan facilities of up to 25 mill. kr. in 2 tranches (convertible at share price 10). The company is now in a much stronger financial position, which ensures ongoing development of uTRACE/uTREAT according to plan. In my opinion, the foundation has now been created to maintain focus on pure execution.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
14 päivää sitten36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenHow much further down do we expect it to go in the next couple of weeks/months? And how far along are they with finding a patient for dosing?1 t sitten1 t sittenTämä kommentti on poistettu.·1 t sittenAccording to the protocol for this trial, it will conclude in May. But it may well be that they conclude it earlier depending on how quickly they achieve the desired number of patients. I think the next trial will come as soon as possible after if this trial has good results. If adjustments etc. need to be made, then it's impossible to know when the next trial will start. uTREAT is still untested. But both the binding to uPAR and the use of Lutetium-177 are known. Lutetium-177 is already approved for cancer treatment. So I maintain faith even if the first trial doesn't go 100% as hoped.
- ·4 t sittenIt's surely a strong signal that CURA both announces and executes a directed issue at or around the same time after close, and now holds an extraordinary general meeting, among other things, to allow a third-party lender to come into play: "The Board plans to use the authorization to issue a convertible loan note to a third-party lender who supports the planned Directed Issue, as described in the press release dated December 12, 2025 as part of the agreement with the aforementioned third-party investor." 💪·3 t sittenA scenario could well be that it reaches 11-12 before the year is over It's probably not crazy to call this a power move. I am truly impressed, because the timing is nothing short of fantastic and the issue has been completely dismantled, allowing full focus on the pipeline I am 90% sure that in a month, not only will it be forgotten, but it will stand as a decisively correct move from management's side. In addition to gaining peace for the pipeline, one also gains peace for potentially being acquired without having to sell oneself too cheaply.
- ·5 t sittenPositive with more media coverage this morning, I wonder if we'll get a bit more attention around Curasight and their groundbreaking research in the near future - which will certainly also positively affect the stock.! Exciting week ahead….
- ·5 t sittenMany of the sellers in this case are "behind the curve" sellers. Hobby investors who are tired of themselves and that they have gambled the family's savings and in the name of greed failed to sell at 11-12 So they are selling now and entering too late again, and selling too late and buying too late etc. People need to take a breath. YES it will fall the next few days, but just check the development since summer and consider that this directed issue was a bullseye in terms of speed and timing. A huge victory for existing investors, who now avoid an ugly moment of uncertainty for the next 7-8 weeks.
- ·5 t sittenInteresting to see if people sell in panic and forget all about the good that awaits just around the corner·5 t sitten · MuokattuNo, it's good timing, The cash register would have been empty during February (= ongoing operation of the company would be at risk). The share price is high now while we await FPD and effect at uTREAT. They have received 16.4 mill to secure ongoing operations (share price 8) against limited dilution. They have refinanced loans for 10 mill. and secured new loan facilities of up to 25 mill. kr. in 2 tranches (convertible at share price 10). The company is now in a much stronger financial position, which ensures ongoing development of uTRACE/uTREAT according to plan. In my opinion, the foundation has now been created to maintain focus on pure execution.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 250
Myynti
Määrä
2 709
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | AVA | ||
| 2 419 | NON | NON | ||
| 509 | NON | NON | ||
| 401 | NON | NON | ||
| 1 090 | NON | NON |
Ylin
9,72VWAP
Alin
9,14VaihtoMäärä
0,7 78 737
VWAP
Ylin
9,72Alin
9,14VaihtoMäärä
0,7 78 737
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 17 416 | 9 163 | +8 253 | 0 |
| Nordea Bank Abp | 5 604 | 490 | +5 114 | 0 |
| Avanza Bank AB | 10 091 | 5 603 | +4 488 | 750 |
| Danske Bank A/S | 2 451 | 0 | +2 451 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 600 | +400 | 0 |
| Svenska Handelsbanken AB | 0 | 840 | −840 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 42 510 | 59 276 | −16 766 | 31 778 |
| Swedbank AB | 0 | 3 100 | −3 100 | 0 |
| Svenska Handelsbanken AB | 0 | 840 | −840 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 600 | +400 | 0 |
| Danske Bank A/S | 2 451 | 0 | +2 451 | 0 |
| Avanza Bank AB | 10 091 | 5 603 | +4 488 | 750 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
14 päivää sitten36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenHow much further down do we expect it to go in the next couple of weeks/months? And how far along are they with finding a patient for dosing?1 t sitten1 t sittenTämä kommentti on poistettu.·1 t sittenAccording to the protocol for this trial, it will conclude in May. But it may well be that they conclude it earlier depending on how quickly they achieve the desired number of patients. I think the next trial will come as soon as possible after if this trial has good results. If adjustments etc. need to be made, then it's impossible to know when the next trial will start. uTREAT is still untested. But both the binding to uPAR and the use of Lutetium-177 are known. Lutetium-177 is already approved for cancer treatment. So I maintain faith even if the first trial doesn't go 100% as hoped.
- ·4 t sittenIt's surely a strong signal that CURA both announces and executes a directed issue at or around the same time after close, and now holds an extraordinary general meeting, among other things, to allow a third-party lender to come into play: "The Board plans to use the authorization to issue a convertible loan note to a third-party lender who supports the planned Directed Issue, as described in the press release dated December 12, 2025 as part of the agreement with the aforementioned third-party investor." 💪·3 t sittenA scenario could well be that it reaches 11-12 before the year is over It's probably not crazy to call this a power move. I am truly impressed, because the timing is nothing short of fantastic and the issue has been completely dismantled, allowing full focus on the pipeline I am 90% sure that in a month, not only will it be forgotten, but it will stand as a decisively correct move from management's side. In addition to gaining peace for the pipeline, one also gains peace for potentially being acquired without having to sell oneself too cheaply.
- ·5 t sittenPositive with more media coverage this morning, I wonder if we'll get a bit more attention around Curasight and their groundbreaking research in the near future - which will certainly also positively affect the stock.! Exciting week ahead….
- ·5 t sittenMany of the sellers in this case are "behind the curve" sellers. Hobby investors who are tired of themselves and that they have gambled the family's savings and in the name of greed failed to sell at 11-12 So they are selling now and entering too late again, and selling too late and buying too late etc. People need to take a breath. YES it will fall the next few days, but just check the development since summer and consider that this directed issue was a bullseye in terms of speed and timing. A huge victory for existing investors, who now avoid an ugly moment of uncertainty for the next 7-8 weeks.
- ·5 t sittenInteresting to see if people sell in panic and forget all about the good that awaits just around the corner·5 t sitten · MuokattuNo, it's good timing, The cash register would have been empty during February (= ongoing operation of the company would be at risk). The share price is high now while we await FPD and effect at uTREAT. They have received 16.4 mill to secure ongoing operations (share price 8) against limited dilution. They have refinanced loans for 10 mill. and secured new loan facilities of up to 25 mill. kr. in 2 tranches (convertible at share price 10). The company is now in a much stronger financial position, which ensures ongoing development of uTRACE/uTREAT according to plan. In my opinion, the foundation has now been created to maintain focus on pure execution.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 250
Myynti
Määrä
2 709
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | AVA | ||
| 2 419 | NON | NON | ||
| 509 | NON | NON | ||
| 401 | NON | NON | ||
| 1 090 | NON | NON |
Ylin
9,72VWAP
Alin
9,14VaihtoMäärä
0,7 78 737
VWAP
Ylin
9,72Alin
9,14VaihtoMäärä
0,7 78 737
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 17 416 | 9 163 | +8 253 | 0 |
| Nordea Bank Abp | 5 604 | 490 | +5 114 | 0 |
| Avanza Bank AB | 10 091 | 5 603 | +4 488 | 750 |
| Danske Bank A/S | 2 451 | 0 | +2 451 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 600 | +400 | 0 |
| Svenska Handelsbanken AB | 0 | 840 | −840 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 42 510 | 59 276 | −16 766 | 31 778 |
| Swedbank AB | 0 | 3 100 | −3 100 | 0 |
| Svenska Handelsbanken AB | 0 | 840 | −840 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 600 | +400 | 0 |
| Danske Bank A/S | 2 451 | 0 | +2 451 | 0 |
| Avanza Bank AB | 10 091 | 5 603 | +4 488 | 750 |